These innovative compounds represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose https://emiliansbk991615.goabroadblog.com/37993521/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide